Abstract
This review examines the growing literature on the role of peroxisome proliferator-activated receptors (PPARs) in addiction. There are two subtypes of PPAR receptors that have been studied in addiction: PPAR-α and PPAR-γ. The role of each PPAR subtype in common models of addictive behavior, mainly pre-clinical models, is summarized. In particular, studies are reviewed that investigated the effects of PPAR-α agonists on relapse, sensitization, conditioned place preference, withdrawal and drug intake, and effects of PPAR-γ agonists on relapse, withdrawal and drug intake. Finally, studies that investigated the effects of PPAR agonists on neural pathways of addiction are reviewed. Taken together these preclinical data indicate that PPAR agonists are promising new medications for drug addiction treatment.
Keywords: Self-administration, abuse, dependence, stress, nuclear receptors, opioids, nicotine, alcohol, psychostimulants, PPAR.
Current Drug Targets
Title:Peroxisome Proliferator-Activated Receptor (PPAR) Agonists as Promising New Medications for Drug Addiction: Preclinical Evidence
Volume: 14 Issue: 7
Author(s): Bernard Le Foll, Patricia Di Ciano, Leigh V. Panlilio, Steven R. Goldberg and Roberto Ciccocioppo
Affiliation:
Keywords: Self-administration, abuse, dependence, stress, nuclear receptors, opioids, nicotine, alcohol, psychostimulants, PPAR.
Abstract: This review examines the growing literature on the role of peroxisome proliferator-activated receptors (PPARs) in addiction. There are two subtypes of PPAR receptors that have been studied in addiction: PPAR-α and PPAR-γ. The role of each PPAR subtype in common models of addictive behavior, mainly pre-clinical models, is summarized. In particular, studies are reviewed that investigated the effects of PPAR-α agonists on relapse, sensitization, conditioned place preference, withdrawal and drug intake, and effects of PPAR-γ agonists on relapse, withdrawal and drug intake. Finally, studies that investigated the effects of PPAR agonists on neural pathways of addiction are reviewed. Taken together these preclinical data indicate that PPAR agonists are promising new medications for drug addiction treatment.
Export Options
About this article
Cite this article as:
Foll Bernard Le, Ciano Patricia Di, Panlilio Leigh V., Goldberg Steven R. and Ciccocioppo Roberto, Peroxisome Proliferator-Activated Receptor (PPAR) Agonists as Promising New Medications for Drug Addiction: Preclinical Evidence, Current Drug Targets 2013; 14 (7) . https://dx.doi.org/10.2174/1389450111314070006
DOI https://dx.doi.org/10.2174/1389450111314070006 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Application of Freidinger Lactams and their Analogs in the Design of Conformationally Constrained Peptidomimetics
Current Medicinal Chemistry Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Overlapping the Tryptophan Catabolite (TRYCAT) and Melatoninergic Pathways in Alzheimer's Disease
Current Pharmaceutical Design Neurosteroids and Affective Disorders in Women
Current Psychopharmacology Increased Neuronal Injury in Clock Gene Per-1 Deficient-Mice after Cerebral Ischemia
Current Neurovascular Research Tissue-specific Glucocorticoid Signaling May Determine the Resistance Against Glucocorticoids in Autoimmune Diseases
Current Medicinal Chemistry Clozapine Safety, 35 Years Later
Current Drug Safety Hormonal Status Modifies Renin-Angiotensin System-Regulating Aminopeptidases andVasopressin-DegradingActivity in the Hypothalamus-Pituitary-Adrenal Axis of Female Mice
Medicinal Chemistry The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism Drug-Induced Hypothermia in Stroke Models: Does it Always Protect?
CNS & Neurological Disorders - Drug Targets Recent Patents and Patent Applications Relating to mTOR Pathway
Recent Patents on DNA & Gene Sequences FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?
Current Diabetes Reviews The Medical Complications of Anorexia Nervosa and Their Treatments
Current Women`s Health Reviews Neuroprotection by vitamin C against ethanol -induced neuroinflammation associated neurodegeneration in developing rat brain
CNS & Neurological Disorders - Drug Targets Bioactivity and Pharmacological Actions of Carbon Monoxide-Releasing Molecules
Current Pharmaceutical Design Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology The Vigilance Promoting Drug Modafinil Modulates Serotonin Transmission in the Rat Prefrontal Cortex and Dorsal Raphe Nucleus. Possible Relevance for Its Postulated Antidepressant Activity
Mini-Reviews in Medicinal Chemistry Food Addiction and Neuroimaging
Current Pharmaceutical Design Oxidative Imbalance and Anxiety Disorders
Current Neuropharmacology Hypothalamic Leptin and Ghrelin Signaling as Targets for Improvement in Metabolic Control
Current Pharmaceutical Design